aHeart rate <60 bpm.
ALT=alanine transaminase; AST=aspartate transaminase; bpm=beats per minute; CPK=creatine phosphokinase; ILD=interstitial lung disease; ULN=upper limit of normal.
ALECENSA is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene:
Your healthcare provider will perform a test to make sure that ALECENSA is right for you. It is not known if ALECENSA is safe and effective in children.
Everyone reacts differently to treatment with ALECENSA. It’s important to know the most serious and most common side effects with ALECENSA.
Your doctor may lower the dose or stop treatment with ALECENSA if any side effects occur. Contact your healthcare provider right away if you have any of the following side effects.
ALECENSA may cause serious side effects, including:
Liver problems (hepatotoxicity). Liver problems are common with ALECENSA and can be severe. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems:
Lung problems. ALECENSA may cause severe or life-threatening swelling (inflammation) of the lungs during treatment. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening symptoms of lung problems, including:
Kidney problems. ALECENSA may cause severe kidney problems that can lead to death. Tell your healthcare provider right away if you get a change in the amount or color of your urine, or if you get new or worsening swelling in your legs or feet.
Slow heartbeat (bradycardia). ALECENSA may cause very slow heartbeats that can be severe and life-threatening. Your doctor will check your heart rate and blood pressure during treatment with ALECENSA. Tell your doctor right away if you feel dizzy, lightheaded, or faint during treatment with ALECENSA. Tell your doctor if you take any heart or blood pressure medicines.
Severe muscle pain, tenderness, and weakness (myalgia). Muscle problems are common with ALECENSA and can be severe. Treatment with ALECENSA can increase the level of an enzyme called creatine phosphokinase (CPK), which can be a sign of muscle damage. Tell your healthcare provider right away if you have any new or worsening signs and symptoms of muscle problems, including:
Breakdown of healthy red blood cells earlier than normal (hemolytic anemia). Hemolytic anemia can happen in some people who take ALECENSA and may cause you to not have enough healthy red blood cells. Tell your healthcare provider right away if you develop:
Severe increase in blood triglycerides, the most common type of fat in the blood (hypertriglyceridemia). ALECENSA can cause severe increase of levels of fats in the blood called triglycerides, the most common type of fat in the blood, which can lead to life-threatening inflammation of the pancreas (pancreatitis). Tell your healthcare provider right away if you develop any of the following signs and symptoms of pancreatitis:
Your healthcare provider will do blood tests before you start and during treatment with ALECENSA to check for side effects.
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ALECENSA if you have side effects.
What should I tell my doctor before taking ALECENSA?
Before you take ALECENSA, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.
What should I avoid while taking ALECENSA?
Avoid spending time in the sunlight during treatment with ALECENSA and for at least 7 days after stopping ALECENSA. Your skin may be sensitive to the sun (photosensitivity) and you may burn more easily and get severe sunburns. Use sun protecting measures, such as sunscreen and lip balm with SPF 50 or greater to help protect against sunburn.
What are the possible side effects of ALECENSA?
The most common side effects of ALECENSA include:
These are not all of the possible side effects of ALECENSA. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see additional Important Safety Information in full ALECENSA Prescribing Information, including Patient Information.
| Criteria | ALECENSA dose modification |
|---|---|
| ALT or AST elevation of >5X ULN with total bilirubin ≤2X ULN | Temporarily withhold until recovery to baseline or to ≤3X ULN, then resume at reduced dose. See dose reduction schedule. |
| ALT or AST elevation >3X ULN with total bilirubin elevation >2X ULN in the absence of cholestasis or hemolysis | Permanently discontinue ALECENSA. |
| Total bilirubin elevation >3X ULN | Temporarily withhold until recovery to baseline or to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
| Any grade treatment-related ILD/pneumonitis | Permanently discontinue ALECENSA. |
| Grade 3 renal impairment | Temporarily withhold until serum creatinine recovers to ≤1.5X ULN, then resume at reduced dose. See dose reduction schedule. |
| Grade 4 renal impairment | Permanently discontinue ALECENSA. |
| Symptomatic bradycardia | Withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at previous dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose modified, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. See dose reduction schedule. |
| Bradycardiaa (life-threatening consequences, urgent intervention indicated) | Permanently discontinue ALECENSA if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm, with frequent monitoring as clinically indicated. Permanently discontinue ALECENSA in case of recurrence. See dose reduction schedule. |
| CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at same dose. |
| CPK elevation >10X ULN or second occurrence of CPK elevation of >5X ULN | Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at reduced dose. See dose reduction schedule. |
| Hemolytic anemia | Withhold ALECENSA if hemolytic anemia is suspected. Upon resolution, resume at reduced dose or permanently discontinue. See dose reduction schedule. |
aHeart rate <60 bpm.
ALT=alanine transaminase; AST=aspartate transaminase; bpm=beats per minute; CPK=creatine phosphokinase; ILD=interstitial lung disease; ULN=upper limit of normal.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.